T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy

pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited

(2013) P. Snaebjornsson et al.   INTERNATIONAL JOURNAL OF CANCER

Prediction of Cancer Incidence and Mortality in Korea, 2012

(2012) Kyu-Won Jung et al.   Cancer Research and Treatment

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

(2011) Greg Yothers et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of pretreatment hematologic profile on survival of colorectal cancer patients

(2010) Miao-zhen Qiu et al.   TUMOR BIOLOGY

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data

(2009) Leonard L. Gunderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients

(2008) M. Baghi et al.   CLINICAL OTOLARYNGOLOGY

Direct regulation of TWIST by HIF-1α promotes metastasis

(2008) Muh-Hwa Yang et al.   NATURE CELL BIOLOGY

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

(2008) Donald C. McMillan   PROCEEDINGS OF THE NUTRITION SOCIETY